Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B

Hepatology Research

Volumn 40, Issue 5, 2010, Pages 461-469

  Okuse, Chiaki ^a   Yotsuyanagi, Hiroshi ^b   Yamada, Norie ^a   Okamoto, Masaru ^a   Ikeda, Hiroki ^a   Kobayashi, Minoru ^a   Fukuda, Yasunobu ^a   Takahashi, Hideaki ^a   Nagase, Yoshihiko ^a   Suzuki, Yuka ^a   Matsunaga, Kotaro ^a   Ishii, Toshiya ^a   Matsumoto, Nobuyuki ^a   Koike, Kazuhiko ^c   Suzuki, Michihiro ^a   Itoh, Fumio ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kanazawa Medical University   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic hepatitis B; Interferon; Lamivudine; Sequential therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 77954364665     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00639.x     Document Type: Article

References (54)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003, 362:2089-94.
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002, 346:1682-3.
3. Lau DT-Y, Everhart J, Kleiner DE. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997, 113:1660-7.
4. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29:971-5.
5. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009, 49(5):S1031-1. Suppl
6. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009, 49(5):S112-21. Suppl
7. Rang A, Bruns M, Heise T, Will H. Antiviral activity if interferon-α against hepatitis B virus can be studied in non - hepatic cells and independent of MxA. J Mol Chem 2002, 277:7645-7.
8. Peters M, Walling DM, Waggoner J, Avigan MI, Sjogren M, Hoofnagle JH. Immune effects of alpha - interferon in chronic liver disease. J Hepatpl 1986, 3(2):S283-9. Suppl
9. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993, 119:312-23.
10. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986, 4:234-43.
11. Dienstag JL, Schiff ER, Wright TL. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256-63.
12. Marcellin P, Chang TT, Lim SG. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-16.
13. Chang TT, Gish RG, de Man R. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-10.
14. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009, 49(5):S185-95. Suppl
15. van Nunen AB, Hansen BE, Suh DJ. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003, 52:420-4.
16. Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003, 38:545-53.
17. Leung NW, Lai CL, Chang TT. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527-32.
18. Shin JW, Park NH, Jung SW. Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. Antivir Ther 2009, 14:181-6.
19. Mutimer D, Naoumov N, Honkoop P. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998, 28:923-9.
20. Schalm SW, Heathcote J, Cianciara J. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000, 46:562-8.
21. Barbaro G, Zechini F, Pellicelli AM. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001, 35:406-11.
22. Serfaty L, Thabut D, Zoulim F. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001, 34:573-7.
23. Shi M, Wang RS, Zhang H. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. lamivudine-resistant mutations. J Antimicrob Chemother 2006, 58:1031-5.
24. Tatulli I, Francavilla R, Rizzo GL. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001, 35:805-10.
25. Santantonio T, Niro GA, Sinisi E. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002, 36:799-804.
26. Schiff ER, Dienstag JL, Karayalcin S. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003, 38:818-26.
27. Niro GA, Fontana R, Gioffreda D. Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study. Dig Liver Dis 2007, 39:857-63.
28. Janssen HL, van Zonneveld M, Senturk H. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-9.
29. Chan HL, Leung NW, Hui AY. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005, 142:240-50.
30. Marcellin P, Lau GK, Bonino F. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-17.
31. Lau GK, Piratvisuth T, Luo KX. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-95.
32. Bonino F, Marcellin P, Lau GK. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007, 56:699-705.
33. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983, 84:216-9.
34. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987, 92:1839-43.
35. Kim HS, Kim HJ, Shin WG. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2009, 136:505-12.
36. Yuki N, Nagaoka T, Nukui K, Omura M, Hikiji K, Kato M. Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection. J Gastroenterol 2008, 43:457-63.
37. Kimura T, Rokuhara A, Sakamoto Y. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002, 40:439-45.
38. Kimura T, Rokuhara A, Matsumoto A. New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. J Clin Microbiol 2003, 41:1901-6.
39. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M. Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol Res 2000, 17:31-42.
40. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20. The French METAVIR Cooperative Study Group
41. Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985, 89:732-5.
42. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009, 49(5):S129-37. Suppl
43. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003, 39:S111-5.
44. Chang TT, Lai CL, Chien RN. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004, 19:1276-84.
45. Yotsuyanagi H, Yasuda K, Iino S. Short-term lamivudine for the treatment of chronic hepatitis B. Intervirology 2003, 46:367-72.
46. Ghezzi P, Bianchi M, Gianera L, Landolfo S, Salmona M. Role of reactive oxygen intermediates in the interferon-mediated depression of hepatic drug metabolism and protective effect of N-acetylcysteine in mice. Cancer Res 1985, 45:3444-7.
47. Erhardt A, Reineke U, Blondin D. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000, 31:716-25.
48. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002, 123:1848-56.
49. Boni C, Bertoletti A, Penna A. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998, 102:968-75.
50. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001, 34:1225-41.
51. Fattovich G, McIntyre G, Thursz M. Hepatitis B virus precore/core variation and interferon therapy. Hepatology 1995, 22:1355-62.
52. Perrillo RP, Schiff ER, Davis GL. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990, 323:295.
53. Lok AS, Wu PC, Lai CL. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992, 102:2091-7.
54. Fried MW, Piratvisuth T, Lau GK. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47:428-34.